SL Science Holding Ltd (ticker: SLBT) traded at $2.45 on September 10, its lowest level in the past 52 weeks. The price is 83% lower than the 52‑week peak of $14.50 and reflects a 17% decline over the last week. Over the past year the shares have fallen 74.68%.
InvestingPro rates the company’s financial health as "WEAK" with a score of 1.02 and notes that the stock generally exhibits high price volatility.
The firm presented pre‑clinical research on a glioblastoma treatment at the 2026 World Congress of Basic and Clinical Pharmacology. The work was conducted with Taipei Medical University, JY Biomedical Co., Ltd. and HeXun Biosciences Co., Ltd. SL Science has also filed a request with the U.S. Food and Drug Administration’s Office of Orphan Products Development for orphan‑drug designation for its Vdelta2+ Gamma Delta T‑cell therapy targeting glioblastoma multiforme, which is currently under review.
